Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

Risk Factors in Atopic Dermatitis for the Development of Eczema Herpeticum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00438022
• Other study ID #: DAIT ADVN ADEH 06
• Secondary ID: HHSN266200400029
• Status: Completed
• Phase: N/A
• First received: February 20, 2007
• Last updated: October 4, 2016
• Start date: March 2006
• Est. completion date: January 2010

Study information

• Verified date: October 2016
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema. Eczema herpeticum (EH) is a type of eczema that spreads due to an underlying herpes virus infection. The purpose of this research study is to identify the risk factors that may cause EH.

Description:

AD is characterized by chronic skin inflammation and infections. It is hypothesized that AD is caused by irritants in the environment and that symptoms of EH become worse with stress and changes in hormone levels. This study will examine skin cells collected from study participants to determine the risk factors for EH that are present in people with AD who develop EH.

This study will examine dendritic cells (DC) from the skin and blood of study participants to determine the differences between DCs of study participants. This study will recruit four types of participants:

• Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)

• Group 2 will include participants with AD and recurring HSV infections but without EH

• Group 3 will include participants with AD but without EH or HSV infection

• Group 4 will include participants in good general health without AD, EH, or HSV infection

At the single study visit, skin and blood collection will occur.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria for Participants with AD:

• Diagnosis of AD as defined by ADVN standardized diagnostic criteria who fall into one of the following categories:

1. Recurrent, clinically manifested HSV infection with EH

2. Recurrent, clinically manifested HSV infection without EH

3. No recurrent, clinically manifested HSV infection or EH infection

Inclusion Criteria for All Participants

• Residing in Germany

• Good general health other than having an atopic disease

• Caucasian

• Individuals between 18-60 years of age

Exclusion Criteria for All Participants:

• Subjects with atopy but lacking stringent AD features, allowing only a presumptive diagnosis of AD

• Individuals under 18 or over 60 years of age

• Systemic immunosuppressive drugs or chemotherapy 30 days prior to study entry

• Oral and topical corticosteroids (including inhaled agents), antibiotics, antivirals, anti-inflammatory biologics (e.g., alefacept, etanercept), topical doxepin, topical coal tar preparations, or topical phosphodiesterase inhibitors 14 days prior to study entry

• Immunotherapy

• Antibiotics, antivirals, immune enhancers (e.g., imiquimod), or calcineurin inhibitors within 7 days prior to study entry

• Phototherapy (e.g., ultraviolet light B [UVB], psoralen plus ultraviolet light A [PUVA]) 30 days prior to study entry

• Cancer, autoimmune diseases, or immunodeficiency

• Active fungal, bacterial, or viral infections at screening

• Any skin diseases other than AD that might compromise the stratum corneum barrier (e.g., ichthyosis, bullous disease, psoriasis, skin cancer)

• Mental illness or a history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements

• Inability or unwillingness of a subject to give written informed consent

• Weigh less than 40 kg (88.2 lb)

• Anxiolytic agents

• Antidepressants

• Pregnancy or breastfeeding

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema
• Eczema Herpeticum

Locations

Country	Name	City	State
Germany	University of Bonn, Germany	Bonn

Sponsors (2)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Atopic Dermatitis and Vaccinia Network

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Hinz T, Zaccaro D, Byron M, Brendes K, Krieg T, Novak N, Bieber T. Atopic dermo-respiratory syndrome is a correlate of eczema herpeticum. Allergy. 2011 Jul;66(7):925-33. doi: 10.1111/j.1398-9995.2010.02538.x. Epub 2011 Jan 24. — View Citation

Peng WM, Yu CF, Allam JP, Oldenburg J, Bieber T, Hoch J, Eis-Hübinger AM, Novak N. Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. Hum Immunol. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunohistochemistry will be used to confirm the expression of IgE receptors and IgE binding of myeloid and plasmacytoid Dendritic Cells.		3 years	No
Secondary	The capacity of myeloid and plasmacytoid DCs to produce IFN-a/IFN-ß and of myeloid DCs to produce IL-10, IL-12, and IL-18 will be evaluated.		3 years	No
Secondary	Expression of HSV-receptors cluster of differentiation, costimulatory molecules, major histocompatibility complex, Toll-like receptor (TLR), and structures involved in antigen presentation of myeloid and plasmacytoid DCs.		3 years	No
Secondary	Evaluate the capacity of T-cells, stimulated and unstimulated myeloid DCs or plasmacytoid DCs to produce the T-helper cell 2 (Th2) cytokines IL-4, IL-5 and IL-13 and the T-helper cell 1 (Th1) cytokines IL-2 and IFN-? and IL-10/TGF-ß.		3 years	No
Secondary	The phenotype of T-cells cocultured with HSV/CpG stimulated and unstimulated myeloid DCs or plasmacytoid DCs will be evaluated by flow cytometry.		3 years	No
Secondary	The proliferation of T-cells cocultured with HSV/CpG stimulated and unstimulated myeloid DCs or plasmacytoid DCs will be measured with the help of flow cytometry by proliferating cell nuclear antigen.		3 years	No

External Links

•   National Institute of Allergy and Infectious Diseases (NIAID) Website